Sign In

Big VC rounds for Ganymed and MISSION to fight cancer

18 November 2013 17:47
By Tornado Staff

Today saw two big investments in life sciences companies that develop treatments for cancer.

The biggest investment was received by German biopharmaceutical company Ganymed Pharmaceuticals, which develops highly selective Ideal Monoclonal Antibodies (IMABs) for the treatment of cancer. The series E round totaled €45 million and was raised from existing investors ATS Beteiligungsverwaltung, MIG Fond, and FCPB Gany.

Ganymed will use the proceeds to accelerate the clinical development of its lead program IMAB362, including completion of the ongoing phase IIa and IIb clinical trials in gastroesophageal cancer and to prepare this first-in-class antibody for a phase III study. Also, the company will clinically validate its IVD test, CLAUDETECT18.2, as a predictive companion diagnostic test to IMAB362. Finally, the financing will help Ganymed to conduct a phase I/II clinical study of IMAB027 in ovarian cancer and develop a companion diagnostic test for this antibody.

Meanwhile, UK-based biotech company MISSION Therapeutics received a €23.8 million series B funding round from new investor Pfizer Venture Investments and existing backers Imperial Innovations Group, Sofinnova Partners, SR One and Roche Venture Fund. MISSION will use the current financing round to advance its lead programs for the treatment of various genetically defined cancers, through preclinical development and further development of its technology platform.

MISSION has progressed several small molecule discovery programs focused on key enzymes in the ubiquitin pathway to selectively target difficult-to-treat cancers. By targeting such ‘deubiquitylating’ enzymes (DUBs) which are involved in the DNA damage response, the company aims to induce synthetic lethality, a mechanism for the selective killing of tumor cells characterized by specific genetic abnormalities.

Related stories
Mucosis wins Wellcome Trust award and backing from current investors
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Catalan medical diagnostics company STAT-Diagnostica gets €17 million


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 13€2.8MBusiness applications
Oct 11€13.0MGames
Oct 11€10.0MSecurity
Oct 11€1.2MInternet commerce
Oct 11€3.4MWireless applications
Oct 10€1.7MInternet services
Oct 10€0.9MWireless applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.